Vnitr Lek 2017, 63(4):249-253 | DOI: 10.36290/vnl.2017.052

The role of cardiovascular magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy. Part II

Martin Pleva1,2,*, Júlia Borová1, Ilona Plevová3, Jaroslav Januška1, Margita Belicová4
1 Komplexní kardiovaskulární centrum Nemocnice Podlesí a.s., Třinec
2 Vaskulární centrum Vítkovické nemocnice, a.s., Ostrava
3 Ústav ošetřovatelství a porodní asistence LF OU, Ostrava
4 I. interná klinika JLF UK a UNM, Martin, Slovenská republika

Hypertrophic cardiomyopathy is currently understood as a group of diseases with left ventricular hypertrophy, which are not based on adaptive mechanisms. The first part of the review details the possibility of cardiac magnetic resonance in the diagnosis of sarcomeric forms of hypertrophic cardiomyopathy, the second part will focus on the possibilities of distinguishing the sarcomeric forms from their phenocopies.

Keywords: cardiac magnetic resonance; hypertrophic cardiomyopathy; phenocopies

Received: November 5, 2016; Accepted: March 13, 2017; Published: April 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Pleva M, Borová J, Plevová I, Januška J, Belicová M. The role of cardiovascular magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy. Part II. Vnitr Lek. 2017;63(4):249-253. doi: 10.36290/vnl.2017.052.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Elliott PM, Anastasakis A, Borger MA et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 2014; 35(39):2733-2779. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehu284>. Go to original source... Go to PubMed...
    2. Fagard RH. Athlete's heart or hypertrophic cardiomyopathy. Heart Metab 2012; 56: 14-19. Dostupné y WWW: <https://www.heartandmetabolism.com/download/56/4.pdf>.
    3. Petersen SE, Selvanayagam JB, Francis JM et al. Differentiation of athlete's heart from pathological forms of cardiac hypertrophy by means of geometric indices derived from cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2005; 7(3): 551-558. Go to original source... Go to PubMed...
    4. Rubinshtein R, Glockner JF, Ommen SR et al. Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced magnetic resonance imaging in patients with hypertrophic cardiomyopathy. Circ Heart Fail 2010; 3(1): 51-58. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCHEARTFAILURE.109.854026>. Go to original source... Go to PubMed...
    5. Rudolph A, Abdel-Aty H, Bohl S et al. Noninvasive detection of fibrosis applying contrast-enhanced cardiac magnetic resonance in different forms of left ventricular hypertrophy. Relation to remodeling. J Am Coll Cardiol 2009; 53(3): 284-291. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2008.08.064>. Go to original source... Go to PubMed...
    6. Sipola P, Magga J, Husso M et al. Cardiac MRI assessed left ventricular hypertrophy in differentiating hypertensive heart disease from hypertrophic cardiomyopathy attributable to a sarcomeric gene mutation. Eur Radiol 2011; 21(7): 1383-1389. Dostupné z DOI: <http://dx.doi.org/10.1007/s00330-011-2065-y>. Go to original source... Go to PubMed...
    7. Dabir D, Child N, Kalra A et al. Reference values for healthy human myocardium using a T1 mapping methodology: results from the International T1 Multicenter cardiovascular magnetic resonance study. J Cardiovasc Magn Reson 2014; 16: 69. Dostupné z DOI: <http://dx.doi.org/10.1186/s12968-014-0069-x>. Go to original source... Go to PubMed...
    8. Moon JC, Messroghli DR, Kellmanet P et al. Myocardial T1 mapping and extracellular volume quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement. J Cardiovasc Magn Reson 2013; 15: 92. Dostupné z DOI: <http://dx.doi.org/10.1186/1532-429X-15-92>. Go to original source... Go to PubMed...
    9. Linhartová K. Restriktivní kardiomyopatie. In: Veselka J, Linhartová K, Zemánek D et al. Kardiomyopatie. Galén: Praha 2009: 57-87. ISBN 978-80-7262-640-3.
    10. Banypersad SM, Moon JC, Whelan C et al. Updates in cardiac amyloidosis: a review. J Am Heart Assoc 2012; 1(2): e000364. Dostupné z DOI: <http://dx.doi.org/10.1161/JAHA.111.000364>. Go to original source... Go to PubMed...
    11. Sipe JD, Benson MD, Buxbaum JN et al. Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines. Amyloid 2016; 23(4): 209-213. Go to original source... Go to PubMed...
    12. Ščudla V, Pika T, Látalová P et al. Diagnostika a stratifikace systémové AL amyloidózy ve světle "Doporučení České myelomové skupiny 2013". Klin Biochem Metab 2014; 22(2): 49-60.
    13. Syed IS, Glockner JF, Feng DL et al. Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. JACC Cardiovasc Imaging 2010; 3(2): 155-164. Dostupné z DOI: http://dx.doi.org/10.1016/j.jcmg.2009.09.023>. Go to original source... Go to PubMed...
    14. Maceira AM, Joshi J, Prasad SK et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 2005; 111(2): 186-193. Go to original source... Go to PubMed...
    15. Maceira AM, Prasad SK, Hawkins PN et al. Cardiovascular magnetic resonance and prognosis in cardiac amyloidosis. J Cardiovasc Magn Reson 2008; 10: 54. Dostupné z DOI: <http://dx.doi.org/10.1186/1532-429X-10-54>. Go to original source... Go to PubMed...
    16. Vogelsberg H, Mahrholdt H, Deluigi CC et al. Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis noninvasive imaging compared to endomyocardial biopsy. J Am Coll Cardiol 2008; 51(10): 1022-1030. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2007.10.049>. Go to original source... Go to PubMed...
    17. Karamitsos TD, Piechnik SK, Banypersad SM et al. Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging 2013; 6(4): 488-497. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jcmg.2012.11.013>. Go to original source... Go to PubMed...
    18. Banypersad SM, Fontana M, Maestrini V et al. T1mapping and survival in systemic light-chain amyloidosis. Eur Heart J 2015; 36(4): 244-251. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehu444>. Go to original source... Go to PubMed...
    19. Goláň L. Fabryho choroba-lysozomální onemocnění ze střádání s multiorgánovým postižením. Interní Med 2012; 14(10): 378-382.
    20. Linhart A, Elliott PM. The heart in Anderson-Fabry disease and other lysosomal storage disorders. Heart 2007; 93(4): 528-535. Go to original source... Go to PubMed...
    21. Sachdev B, Takenaka T, Teraguchi H et al. Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation 2002; 105(12): 1407-1411. Go to original source... Go to PubMed...
    22. Paleček T, Honzíková J, Poupětová H et al. Prevalence of Fabry disease in male patients with unexplained left ventricular hypertrophy in primary cardiology practice: prospective Fabry cardiomyopathy screening study (FACSS). J Inherit Metab Dis 2014; 37(3): 455-460. Dostupné z DOI: <http://dx.doi.org/10.1007/s10545-013-9659-2>. Go to original source... Go to PubMed...
    23. De Cobelli F, Esposito A, Belloni E et al. Delayed-enhanced cardiac MRI for differentiation of Fabry's disease from symmetric hypertrophic cardiomyopathy. AJR Am J Roentgenol 2009; 192(3): W97-W102. Dostupné z DOI: <http://dx.doi.org/10.2214/AJR.08.1201>. Go to original source... Go to PubMed...
    24. Deva DP, Li Q, Ng MY et al. Cardiovascular magnetic resonance demonstration of the spectrum of morphological phenotypes and patterns of myocardial scarring in Anderson-Fabry disease. J Cardiovasc Magn Reson 2016; 18: 14. Dostupné z DOI: <http://dx.doi.org/10.1186/s12968-016-0233-6>. Go to original source... Go to PubMed...
    25. Sado DM, White SK, Piechnik SK et al. Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance moncontrast myocardial T1 mapping. Circ Cardiovasc Imaging 2013; 6(3): 392-398. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCIMAGING.112.000070>. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.